The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
October 31st 2024
Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.
October 23rd 2024
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPC
January 5th 2024Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.
177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer
Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.
Lutetium Lu 177 Vipivotide Tetraxetan Addresses Unmet Need in Taxane-Naive mCRPC
Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.
TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?
December 18th 2023Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.
Novel Combination Regimens Are Expanding the Prostate Cancer Treatment Paradigm
December 1st 2023Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.
Pembrolizumab Plus Enzalutamide/ADT Fails to Improve rPFS in mHSPC
The addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) and androgen deprivation therapy did not improve radiographic progression-free survival vs placebo plus enzalutamide and ADT in patients with metastatic hormone-sensitive prostate cancer, according to data from the phase 3 KEYNOTE-991 trial presented at the 2023 ESMO Congress.
BXCL701/Pembrolizumab Combo Prolongs OS in mCRPC of Adenocarcinoma Phenotype
Treatment with the oral innate immune activator BXCL701 combined with pembrolizumab demonstrated prolonged overall survival in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype.
STEAP1 Offers Potential Multifunctional Target in Prostate Cancer
Because STEAP1 is often overexpressed in prostate cancer, a disease that still largely lacks safe and effective treatment options, investigators are using it as the basis for developing novel therapies.